30-06-2025
Sage Therapeutics cuts more than 330 jobs after announcing its $795 million acquisition
Sage and Supernus could not immediately be reached for comment.
With its planned purchase of Sage, Supernus will have access to Zurzuvae, the only postpartum depression drug approved by the Food and Drug Administration.
'This acquisition represents a major step in bolstering our future growth,' Supernus CEO Jack Khattar said in a statement.
Advertisement
The deal is expected to close in the third quarter of this year.
The last few years have been rocky for Sage, which was founded in 2010 to research treatments for brain diseases and went public in 2014.
The FDA failed to approve Zurzuvae to treat the more common major depressive disorder in 2023. Sage codeveloped the drug with Biogen, another Cambridge biotech.
In August 2023, Sage
Sage rejected a $469 million acquisition offer from Biogen in January, stating the offer undervalued the company.
Advertisement
Supernus, which has existed in different iterations for three decades, specializes in diseases of the central nervous system. The company has several commercial products for the treatment of Parkinson's disease, attention deficit/hyperactivity disorder, epilepsy and migraines.
Marin Wolf can be reached at
